Arcellx ACLX 深 沪
交易中 05-11 11:53:17 美东时间
115.05
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 115.05
- 总市值 411.15万
- 52周最高 115.13
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 53.07
- 委 比 0.00%
- 总股本 3.57万
- 历史最高 115.13
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.10
- 每 手 1
- 风险率 17.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cantor Fitzgerald Suspends Neutral Rating on Arcellx
Cantor Fitzgerald suspends Neutral rating on Arcellx (NASDAQ:ACLX).
04-29 23:00
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal
Gilead shares dip after $3.15 billion Tubulis deal adds ADC asset, as multiple acquisitions reshape oncology and autoimmune pipeline outlook.
04-08 00:06
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition
Gilead to acquire Ouro Medicines for $1.675 billion, explores Galapagos collaboration, outlines cost-sharing and royalty terms.
03-25 01:58
Dow Tumbles Over 700 Points; Dominion Energy Posts Upbeat Earnings
U.S. stocks traded lower midway through trading, with the Dow Jones index dippi...
02-24 02:36
Needham Downgrades Arcellx to Hold
Needham analyst Gil Blum downgrades Arcellx (NASDAQ:ACLX) from Buy to Hold.
02-24 00:12
Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug
Gilead Sciences to acquire Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy for cancer.
02-23 20:51
Why Is Arcellx Stock Surging Today?
Arcellx shares updated ASH data showing strong response and survival results for anito-cel in relapsed multiple myeloma, with analysts highlighting its emerging profile.
2025-12-09 02:23
Reported Saturday, Anito-Cel Demonstrates 96% ORR And 74% CR/sCR In iMMagine-1 Relapsed/Refractory Multiple Myeloma, Supporting Planned 2026 Commercial Launch
Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses continue to deepen over time --Overall MRD negativity was 95% and sustained MRD negativity for >6 months was 83%, both at
2025-12-08 16:47
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
Aclaris Therapeutics starts Phase 2 trial of bosakitug for moderate-to-severe atopic dermatitis. Bosakitug shows strong potency and affinity to TSLP, with top line results expected in H2 2026.
2025-06-02 10:59
Cantor Fitzgerald Reiterates Overweight on Arcellx
Cantor Fitzgerald analyst Josh Schimmer reiterates Arcellx (NASDAQ:ACLX) with a Overweight.
2024-09-10 00:45
